State Of Wyoming Argenx Se Transaction History

State Of Wyoming

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$356.95 - $413.29 $71,390 - $82,658	200 New	200 $78,000
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $48,254 - $67,819	-179 Reduced 65.33%	95 $36,000
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $9,414 - $12,989	37 Added 15.61%	274 $86,000
Q4 2021 Feb 11, 2022	BUY	$272.01 - $353.03 $5,168 - $6,707	19 Added 8.72%	237 $83,000
Q3 2021 Feb 11, 2022	SELL	$295.0 - $350.58 $61,950 - $73,621	-210 Reduced 49.07%	218 $66,000
Q2 2021 Feb 11, 2022	BUY	$257.11 - $319.92 $61,449 - $76,460	239 Added 126.46%	428 $129,000
Q1 2021 Feb 08, 2022	BUY	$268.3 - $380.31 $50,708 - $71,878	189 New	189 $52,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.